通过MRD检测优化或调整治疗策略,已成为CLL/SLL临床研究的重要方向。这些创新策略不仅有助于减少过度治疗带来的不良反应,还为CLL/SLL患者实现更长的无病生存创造了条件。在今年ASH上,荷兰Albert Schweitzer医院的Mark-David Levin教授报告了...
MRD-directed therapy in CLL: ready for prime time? Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):413-420. 江倩 国家中心PI 、教授 主任医师、博导 国家血液系统疾病临床医学研究中心 北京大学人民医院 北京大学血液病研究所 魏蓉 ...
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaWe designed a trial in which postremission therapy of young patients with de novo acute myeloid leukemia (AML) was decided combining cytogenetics/genetics and postconsolidation levels...
an analysis from the UK phase III FLAIR trial showed improved progression-free survival with measurable residual disease (MRD)-guided ibrutinib/venetoclax vs fludarabine/cyclophosphamide/rituximab (FCR) in patients with untreated chronic lymphocytic leukemia (CLL). ...
sensitivity when the assay is based on analysing intact cells or RNA or DNA extracted from intact cells. In chronic lymphocytic leukaemia (CLL), for example, residual leukaemia cells in spleen and lymph nodes are unlikely to be identified in MRD-tests done on blood or bone marrow samples, a...
Moreover, in CLL residual leukaemia cells in lymph nodes and spleen are unlikely to be detected by MRD-testing of blood and/or bone marrow samples. This limitation may be overcome by testing blood samples for cell-free DNA (cfDNA) [39]. Apart from choosing an appropriate sampling site the...
ICAM-1 CAR T-Cell Therapy Shows Promise in Aggressive Thyroid Cancers CLL/SLL Treatment: Could Statins Play a Protective Role? CLL & Statins: A Surprising Link Genetic Ancestry of Patients With High-Risk Melanoma: Tarhini’s Insights SunRISe-1 Highlights TAR-200 as Alternative to Surgery for ...
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trialdoi:10.1182/bloodadvances.2024013182Adriano VendittiAlfonso PiciocchiAnna CandoniValentina ArenaRaffaele PalmieriCarla FilìAngelo Michele Carella...
Based on these results, SCS MRD assessment may be useful for informing treatment decisions in first remission and for following clonal evolution during and after conventional therapy in AML. Acknowledgments The authors thank Mission Bio for providing assistance with data generation, data analysis, and ...
随着CLL治疗的不断发展,治疗终点也需要重新定义。检测可测量的残留疾病(MRD)是一种灵敏的检测手段,可用于确定CLL使用多种治疗方案(包括CIT、基于维奈克拉的方案和细胞疗法)治疗后的疾病负荷,已被证明具有预后价值。但在临床实践中,以MRD为导向的治疗和根除MRD...